About sodium hyaluronate cross-linked
Sodium hyaluronate cross-linked manufacturers include Allergan Aesthetics (Juvéderm), Galderma (Restylane), Teoxane, Merz and Sanofi (Synvisc), plus raw material producers such as Bloomage Biotech in China. Cross-linked sodium hyaluronate is hyaluronic acid whose chains are chemically linked to form a long-lasting gel. It is used mainly in dermal fillers for facial volume and wrinkles, and in joint injections (viscosupplements) for knee osteoarthritis. These products are usually regulated as medical devices. Companies can source cross-linked hyaluronic acid gels and finished products through supply, private label or licensing.
Sodium hyaluronate cross-linked key facts
|
Property |
Sodium hyaluronate cross-linked |
|---|---|
|
Name |
Cross-linked sodium hyaluronate; cross-linked hyaluronic acid (HA) |
|
Source of HA |
Bacterial fermentation (mainly Streptococcus species) |
|
Common cross-linkers |
BDDE (1,4-butanediol diglycidyl ether) for most fillers; divinyl sulfone (hylan G-F 20) |
|
Main uses |
Dermal fillers; intra-articular viscosupplements for osteoarthritis |
|
Filler brands |
Juvéderm (Allergan Aesthetics / AbbVie); Restylane (Galderma); Teosyal (Teoxane); Belotero (Merz) |
|
Viscosupplement brands |
Synvisc, Synvisc-One (hylan G-F 20, Sanofi); Durolane; Monovisc |
|
Dosage form |
Sterile gel in prefilled syringes, often with lidocaine (fillers) |
|
Regulatory class |
Medical device: EU Class III (MDR); US PMA (Class III) |
|
Indications (fillers) |
Correction of facial wrinkles and folds; lip and facial volume restoration |
|
Indications (viscosupplements) |
Pain from knee osteoarthritis not responding to other treatment |
|
Raw material producers |
Bloomage Biotech and other Chinese producers; European and Japanese producers |
|
Generic status |
Not applicable; each product approved separately as a device |
Sodium hyaluronate cross-linked manufacturers and licensing history
Cross-linked hyaluronic acid became widely used in medicine in the 1990s. Hylan G-F 20 (Synvisc), a joint injection for knee osteoarthritis, was approved in the US in 1997. Restylane, developed by Q-Med and now owned by Galderma, became the first HA dermal filler approved in the US in 2003, followed by Juvéderm.
The dermal filler market is led by Allergan Aesthetics (part of AbbVie) and Galderma, with Teoxane, Merz and many Korean and Chinese producers. Most hyaluronic acid raw material is now produced in China by fermentation, with Bloomage Biotech among the largest producers.
Products differ in HA concentration, cross-linking degree, particle size and gel strength, which affect how long they last. Buyers should confirm medical device certification (CE mark under MDR or FDA PMA), residual BDDE levels, endotoxin data and clinical evidence before choosing a supplier.
Sodium hyaluronate cross-linked dosage forms and dossier types
Cross-linked sodium hyaluronate is supplied as sterile gels in prefilled syringes.
|
Form |
Strengths |
Typical dossier |
Notes |
|---|---|---|---|
|
HA dermal filler gel |
Typically 15–25 mg/ml HA; often 0.3% lidocaine |
EU MDR Class III; US PMA |
Main aesthetic form |
|
HA viscosupplement (single or multiple injection) |
Per product |
EU MDR Class III; US PMA |
Knee osteoarthritis |
|
Cross-linked HA bulk gel / raw HA |
Bulk |
Supplier documentation; device master file |
Medical or cosmetic grade |
|
Target market |
Dossier format |
Key requirement |
|---|---|---|
|
European Union |
MDR technical documentation (Class III) |
Notified body review; clinical evaluation |
|
United States |
PMA |
Clinical trials per indication |
|
China, Korea, other markets |
National device registration |
Local clinical data often required |
Sodium hyaluronate cross-linked regulatory and patent status
Cross-linked hyaluronic acid products are usually regulated as Class III medical devices. In the EU, they need CE marking under the Medical Device Regulation, with notified body review and clinical evaluation. In the US, they need premarket approval (PMA). Each product is approved separately, and cross-linking technologies are often protected by patents.
Sodium hyaluronate cross-linked mechanism of action and therapeutic use
Hyaluronic acid binds large amounts of water. Cross-linking makes it resist breakdown, so it stays in place for months. In dermal fillers, it adds volume and smooths wrinkles, lasting about 6–18 months. In joints, it improves the lubricating and shock-absorbing properties of joint fluid, which can reduce knee osteoarthritis pain. The effect can be reversed with the enzyme hyaluronidase.
Sodium hyaluronate cross-linked licensing and sourcing
Cross-linked sodium hyaluronate suppliers typically offer finished device supply, private label, regional distribution or raw material supply. Buyers usually compare device certification, clinical data, gel properties and territory availability. Current offers and supplier contacts are listed among the sodium hyaluronate cross-linked manufacturers on Pipelinepharma.
Frequently asked questions about sodium hyaluronate cross-linked
Who are the main cross-linked sodium hyaluronate manufacturers? Allergan Aesthetics (Juvéderm), Galderma (Restylane), Teoxane and Merz lead in dermal fillers. Sanofi makes Synvisc for joints, and Bloomage Biotech is a major raw material producer.
Is cross-linked hyaluronic acid a drug or a device? In the EU and US, most cross-linked HA fillers and joint injections are regulated as Class III medical devices.
What is the difference between cross-linked and non-cross-linked hyaluronic acid? Cross-linked HA is chemically linked into a gel that lasts for months. Non-cross-linked HA breaks down quickly and is used in eye drops, skin care and some joint injections.
What is BDDE? BDDE (1,4-butanediol diglycidyl ether) is the most common cross-linker in HA fillers. Residual BDDE levels must be tightly controlled.
How long do cross-linked hyaluronic acid fillers last? Most HA fillers last about 6–18 months, depending on the product and treatment area.
Popular Searches
Want unlimited access to the Pipelinepharma database?
Become a subscriber to unlock:
-
Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.
-
Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.
-
Higher profitability: compare multiple supplier offers and secure the best commercial terms.
-
Expanded network: view supplier portfolios and stay updated on new products.
-
Value-added product ideas: discover products with lower competition potential.
-
Access to marketing authorizations for sale: find already registered products in your target markets.